Bitopertin Meets Primary Phase 2 Endpoint in Erythropoietic Protoporphyria : vimarsana.com

Bitopertin Meets Primary Phase 2 Endpoint in Erythropoietic Protoporphyria

Topline results from AURORA indicate that while bitopertin significantly reduced PPIX levels, improvements in light tolerance were not statistically significant.

Related Keywords

Matt Brown Unsplash , John Quisel , Drug Administration , Disc Medicine Inc , Patient Global Impression , Disc Medicine ,

© 2024 Vimarsana